University of California, San Francisco
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of California, San Francisco sits in the top decile of US sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count).
University of California, San Francisco: 1,713 sponsored US clinical trials, 272 recruiting.
University of California, San Francisco sponsors 1,713 registered US clinical trials on ClinicalTrials.gov, 272 of them currently recruiting, and 1,130 completed. 196 of these trials are in Phase 3-4 (later-stage) and 359 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 18 trials.
Top-decile sponsor footprint
University of California, San Francisco ranks in the top decile of sponsors by registered trial count (#10 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,130 of 1,305 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,713 total, page 15 of 35
BIIB092 in Primary Tauopathies: CBS, nfvPPA, sMAPT, and TES
NCT03658135
Effect of Location of Tetanic Stimuli on Photoplethysmogram
NCT03648853
WALK Study: Women's Active Living for Koreans Study
NCT03681756
Preventing Loss of Independence Through Exercise (PLIÉ) in Persons With Mild Cognitive Impairment (MCI)
NCT03526146
Perioperative Virtual Reality for Pediatric Anesthesia
NCT03583450
Impact of Photobiomodulation (PBM) on Biomarkers of Alzheimer's Disease
NCT03405662
Determining Normal Range for Free Light Chains in Serum Among Twins
NCT04191057
Youth to Text or Telehealth for Engagement in HIV Care
NCT03681145
User-Friendly Spirometer and Mobile App for Self-Management and Home Monitoring of Asthma Patients
NCT03642418
Immunogenetic Profiling of Goeckerman Therapy in the Treatment of Psoriasis Vulgaris
NCT03662685
Study of Time-restricted Eating on Weight Loss.
NCT03393195
Pilot to Examine Risk and Feasibility of Remote Management of BP From Childhood Into Early Adulthood
NCT03691701
Pioneering Advances in Care and Education (PACE)
NCT03397160
Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant
NCT03619837
Treatment of Asian Flushing Syndrome With Topical Alpha Agonists
NCT03497442
Enhanced Stress Resilience Training for Faculty
NCT03516877
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
NCT03534141
Inpatient Clinical Trial of NAC
NCT03581084
An Electronic Registry to Improve Adherence to Active Surveillance Monitoring at a Safety-net Hospital
NCT03553732
Summertime: Kids in Motion
NCT03947918
Enhanced Stress Resilience Training for Residents
NCT03518359
Ruxolitinib in Operable Head and Neck Cancer
NCT03153982
Customized Registry Tool for Tracking Adherence to Clinical Guidelines for Head and Neck Cancers
NCT03546322
Walnuts to Achieve Lasting NUTrition to Prevent Diabetes
NCT03334175
The Impact of 8 Weeks of a Digital Meditation Application on Work Stress
NCT03527303
BEhavioral EConomics for Oral Health iNnovation Trial
NCT03576326
Web-based Mindfulness Meditation in Reducing Distress in Participants With Metastatic Gastrointestinal Cancer and Their Caregivers
NCT03528863
Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
NCT03316274
Defibrotide TMA Prophylaxis Pilot Trial
NCT03384693
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
NCT03207945
A Facebook Intervention for Young Sexual and Gender Minority Smokers
NCT03259360
Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma
NCT03396952
Pembrolizumab, Capecitabine, and Bevacizumab for Treating Colorectal Cancer
NCT03396926
Integrative Approaches to Cancer Survivorship: Project 3
NCT03479385
Gut Microbiome in Colorectal Cancer
NCT04054908
Strong Futures: A Trial of Two Primary Care Based Interventions to Promote Optimal Health in Latino Infants and Toddlers
NCT03438721
UCSF College Health Study on Contraceptive Training and Education at Community Colleges
NCT03519685
68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
NCT03857087
Digital Cognition in Multiple Sclerosis
NCT03569618
Study of Automated Care Pathway for Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT03028805
Blood Pressure Lowering in Dialysis (BOLD) Trial
NCT03459807
iBeat Wristwatch Validation Study
NCT03711695
Gallium-68 Prostate Specific Membrane Antigen PET in Diagnosing Patients With Thyroid Cancer
NCT03463889
Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
NCT03359863
Self-monitoring and Reminder Texts to Increase Physical Activity After Cancer II
NCT03524716
Technology-Based Intervention to Promote Heart Health After Cardiac Rehab (Mobile4Heart)
NCT03446313
Phono- and Electrocardiogram Assisted Detection of Valvular Disease
NCT03458806
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects
NCT03248570
Folinic Acid in Autism
NCT03771560
Media, Morphokinetics, and Mosaicism
NCT03503877
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 193 |
| Phase 2 | 166 |
| Phase 3 | 44 |
| Phase 4 | 152 |
Therapeutic Areas
What is open in the University of California, San Francisco pipeline
272 recruiting of 1,713 indexed (16% open); 1,130 completed (66%).
Phase mix: 196 late (III/IV) vs 359 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (18 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of California, San Francisco: open-pipeline peers nationwide
Peers matched on 1,713 registered trials and 16% open enrollment, not the therapeutic-area sidebar.
University of California, San Francisco sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,713 trials (± recruiting share)
- Duke University · 1,725 trials · 11% recruiting
- Stanford University · 1,744 trials · 15% recruiting
- VA Office of Research and Development · 1,668 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
Sponsors near 16% open enrollment (± trial volume)
- University of Oregon · 16% recruiting · 63 trials
- Fox Chase Cancer Center · 16% recruiting · 183 trials
- Youngstown State University · 16% recruiting · 19 trials
- ECOG-ACRIN Cancer Research Group · 16% recruiting · 75 trials
Related
What to do with this University of California, San Francisco page
1,713 registered trials is a research-attention snapshot, not an endorsement of University of California, San Francisco or any single study.
- 272 of University of California, San Francisco's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Breast Cancer is the condition University of California, San Francisco studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of California, San Francisco pipeline card: 1,713 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.